79 related articles for article (PubMed ID: 1490694)
1. Possible new therapeutic approach in diabetes mellitus by inhibition of carnitine palmitoyltransferase 1 (CPT1).
Wolf HP
Horm Metab Res Suppl; 1992; 26():62-7. PubMed ID: 1490694
[No Abstract] [Full Text] [Related]
2. Etomoxir: a new approach to treatment of chronic heart failure.
Bristow M
Lancet; 2000 Nov; 356(9242):1621-2. PubMed ID: 11089814
[No Abstract] [Full Text] [Related]
3. Fatty acid oxidation inhibition with PPARalpha activation (FOXIB/PPARalpha) for normalizing gene expression in heart failure?
Rupp H; Rupp TP; Maisch B
Cardiovasc Res; 2005 Jun; 66(3):423-6. PubMed ID: 15914105
[No Abstract] [Full Text] [Related]
4. Aminocarnitine ureidic derivatives as inhibitors of carnitine palmitoyltransferase I.
Tassoni E; Conti R; Gallo G; Vincenti S; Dell'Uomo N; Mastrofrancesco L; Ricciolini R; Cabri W; Carminati P; Giannessi F
ChemMedChem; 2010 May; 5(5):666-9. PubMed ID: 20232438
[No Abstract] [Full Text] [Related]
5. Influence of the carnitine palmitoyltransferase inhibitor POCA on myocardial performance and metabolism of insulin resistant rats.
Rösen P; Reinauer H
Acta Physiol Hung; 1988; 71(2):271-80. PubMed ID: 3389170
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of carnitine palmitoyltransferase-1 and -2 inhibitors on rat heart hypertrophy.
Hülsmann WC; Peschechera A; Schneijdenberg CT; Verkleij AJ
Cardioscience; 1994 Sep; 5(3):193-7. PubMed ID: 7827256
[TBL] [Abstract][Full Text] [Related]
7. [Drug therapy in adult-onset diabetes].
Groop L; Uusitupa M
Duodecim; 1990; 106(9):759-65. PubMed ID: 1670368
[No Abstract] [Full Text] [Related]
8. [Vanadium compounds--a new class of therapeutic agents for the treatment of diabetes mellitus].
Beliaeva NF; Gorodetskiĭ VK; Tochilkin AI; Golubev MA; Semenova NV; Kovel'man IR
Vopr Med Khim; 2000; 46(4):344-60. PubMed ID: 11075417
[TBL] [Abstract][Full Text] [Related]
9. [Clinico-therapeutic experiences with the new hypoglycemic sulfanylurea, glibenclamide].
Arena D; Santeusanio F; Puxeddu A; De Ciuceis P; Migliorini E; Siracusa A; Brunetti P
Clin Ter; 1970 Mar; 52(6):509-23. PubMed ID: 5452996
[No Abstract] [Full Text] [Related]
10. [Indications and limitations of oral hypoglycemic agents in the treatment of diabetes mellitus].
Guillon J; Charbonnel B
Cah Med; 1972 Nov; 13(14):999-1006. PubMed ID: 4646244
[No Abstract] [Full Text] [Related]
11. New therapeutic agents for diabetes mellitus: implications for anesthetic management.
Chen D; Lee SL; Peterfreund RA
Anesth Analg; 2009 Jun; 108(6):1803-10. PubMed ID: 19448205
[TBL] [Abstract][Full Text] [Related]
12. [Therapeutic trial of a new antidiabetic with vascular action: 1702 SE].
Jaillard J; Warembourg H
Lille Med; 1972 Oct; 17(9):Suppl 6:1332-6. PubMed ID: 4657429
[No Abstract] [Full Text] [Related]
13. C75 is converted to C75-CoA in the hypothalamus, where it inhibits carnitine palmitoyltransferase 1 and decreases food intake and body weight.
Mera P; Bentebibel A; López-Viñas E; Cordente AG; Gurunathan C; Sebastián D; Vázquez I; Herrero L; Ariza X; Gómez-Puertas P; Asins G; Serra D; García J; Hegardt FG
Biochem Pharmacol; 2009 Mar; 77(6):1084-95. PubMed ID: 19094968
[TBL] [Abstract][Full Text] [Related]
14. A new therapeutic approach to treat psoriasis by inhibition of fatty acid oxidation by Etomoxir.
Caspary F; Elliott G; Navé BT; Verzaal P; Rohrbach M; Das PK; Nagelkerken L; Nieland JD
Br J Dermatol; 2005 Nov; 153(5):937-44. PubMed ID: 16225603
[TBL] [Abstract][Full Text] [Related]
15. [Glipizide, a new sulfonylurea in the treatment of diabetes mellitus].
Villaseñor A
Prensa Med Mex; 1973; 38(5):211-4. PubMed ID: 4782089
[No Abstract] [Full Text] [Related]
16. [Inhibitors of beta-oxidation of fatty acids (review)].
Kendysh IN
Vopr Med Khim; 1984; 30(2):18-27. PubMed ID: 6377685
[No Abstract] [Full Text] [Related]
17. [Role of oral hypoglycemic agents in the therapeutic approach to diabetic obesity].
Albert J; Ekoé JM
Sem Hop; 1983 Sep; 59(29-30):2135-40. PubMed ID: 6312587
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a long-chain carbamoyl aminocarnitine derivative, a reversible carnitine palmitoyltransferase inhibitor with antiketotic and antidiabetic activity.
Giannessi F; Pessotto P; Tassoni E; Chiodi P; Conti R; De Angelis F; Dell'Uomo N; Catini R; Deias R; Tinti MO; Carminati P; Arduini A
J Med Chem; 2003 Jan; 46(2):303-9. PubMed ID: 12519067
[TBL] [Abstract][Full Text] [Related]
19. Influence of carnitine acyltransferase inhibitors on the performance and metabolism of rat cardiac muscle.
Reinauer H; Adrian M; Rösen P; Schmitz FJ
J Clin Chem Clin Biochem; 1990 May; 28(5):335-9. PubMed ID: 2380671
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of a new sulfonylurea, glipizide, in the treatment of diabetes mellitus].
Ninni M; Castelletta L
Minerva Med; 1973 Oct; 64(71):3725-31. PubMed ID: 4588364
[No Abstract] [Full Text] [Related]
[Next] [New Search]
